Selank is a synthetic heptapeptide derived from tuftsin — a naturally occurring immunomodulatory tetrapeptide. The addition of a Pro-Gly-Pro sequence to the C-terminus of tuftsin dramatically extends its half-life and adds significant anxiolytic (anti-anxiety) properties.
Selank modulates the GABAergic system — the same neurotransmitter system targeted by benzodiazepines — but without the sedation, tolerance, or dependence associated with benzodiazepine drugs. It enhances GABA receptor sensitivity and stabilizes GABA metabolism in the brain.
Simultaneously, Selank influences serotonergic neurotransmission by modulating serotonin (5-HT) metabolism and receptor expression, contributing to its mood-stabilizing effects. It also affects the expression of brain-derived neurotrophic factor (BDNF) and enkephalins (endogenous opioid peptides involved in stress response).
The immune-modulating properties inherited from tuftsin involve activation of monocytes and natural killer cells, enhancement of phagocytosis, and modulation of cytokine expression — providing immune support alongside the neurological benefits.
Selank is an approved pharmaceutical in Russia and has been studied clinically for anxiety, immune modulation, and cognitive function.
Anxiety (Generalized Anxiety Disorder): Russian clinical trials demonstrated that Selank produced anxiolytic effects comparable to benzodiazepines in patients with generalized anxiety disorder, without sedation, cognitive impairment, or withdrawal symptoms. Effects were observed within the first week of treatment.
Immune Function: Studies showed that Selank enhances IL-6 expression, stabilizes enkephalin levels, and modulates the balance of Th1/Th2 immune responses. It increased the functional activity of monocytes by 2-3 fold in immune-compromised subjects.
Gene Expression: Research demonstrated that Selank influences expression of 36 genes involved in inflammatory response, including upregulation of anti-inflammatory pathways and downregulation of pro-inflammatory cascades.
Cognitive Function: While less potent than Semax for pure cognition, Selank has shown improvements in memory consolidation and learning in stressful conditions — consistent with its anxiolytic effects reducing cognitive interference from anxiety.
The following protocols are reported from clinical practice. This is not medical advice. Consult a licensed healthcare provider before starting any peptide therapy.
Selank is administered intranasally. Reported clinical protocols include:
Standard Anxiolytic Protocol: 250–500 mcg intranasally per day, divided into 1–3 doses. Most providers recommend 250 mcg morning and afternoon.
Acute Anxiety / Stressful Periods: 500–750 mcg per day during high-stress periods, with a return to maintenance dosing after.
Common Stack with Semax: 250 mcg Selank + 200–400 mcg Semax, intranasally. This "calm focus" stack is one of the most popular nootropic peptide combinations.
Cycle Length: 2–4 weeks on, 1–2 weeks off. Selank does not appear to produce tolerance at standard doses, so some providers allow extended cycles with monitoring.
Selank has an outstanding safety profile, particularly notable for an anxiolytic compound. Commonly reported effects include mild nasal irritation from intranasal delivery and occasional fatigue at higher doses.
Critically, Selank does not produce the sedation, cognitive impairment, tolerance, or physical dependence associated with benzodiazepines. It does not impair motor function or reaction time. No withdrawal syndrome has been documented after discontinuation. This makes it one of the most attractive anxiolytic options for individuals who need anxiety relief without the risks of traditional anti-anxiety medications.
Verified suppliers with third-party testing and COA documentation. Use code POWER where applicable.
Selank works on the GABAergic system similarly to benzodiazepines but through a different mechanism. In Russian clinical trials, it demonstrated comparable anxiolytic effects without sedation, tolerance, or dependence. However, anyone currently taking prescribed benzodiazepines should work with their physician before making changes. Selank is not FDA-approved for anxiety treatment in the U.S.
Most providers recommend 2–4 week cycles with breaks. While Selank has not shown tolerance or dependence in clinical studies, periodic cycling is considered best practice for peptide therapy. Some providers allow extended use at lower maintenance doses (150–250 mcg/day).
Many users report noticeable anxiety reduction within 15–30 minutes of intranasal administration, with peak effects at 1–2 hours. The anxiolytic effects typically last 4–6 hours. Cumulative benefits (improved baseline anxiety levels) are usually observed after 1–2 weeks of consistent use.
Selank is not a sedative and does not typically impair wakefulness. However, by reducing anxiety and stress-related hyperarousal, many users report improved sleep quality as an indirect benefit. For direct sleep support, DSIP (Delta Sleep Inducing Peptide) is a more targeted option.
Take our 2-minute quiz to get a personalized peptide recommendation based on your goals, experience level, and health priorities.
Take the Peptide Quiz →This content is for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or condition. Always consult with a qualified healthcare provider before starting any peptide therapy or supplement regimen. Peptide protocols described on this page reflect reported clinical practices and published research — not recommendations. Individual results may vary. Read full disclaimer.
Affiliate Disclosure: PeptideOnline.co participates in affiliate programs with suppliers featured on this page. We may earn a commission on qualifying purchases at no additional cost to you. Our editorial content is independent and not influenced by affiliate relationships. Learn more.